Wells Fargo’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-23,021
| Closed | -$794K | – | 7426 |
|
|
2020
Q3 | $794K | Sell |
23,021
-196,148
| -89% | -$4.18M | ﹤0.01% | 4031 |
|
|
2020
Q2 | $3.66M | Buy |
219,169
+12,294
| +6% | +$209K | ﹤0.01% | 2765 |
|
|
2020
Q1 | $2.98M | Sell |
206,875
-33,520
| -14% | -$857K | ﹤0.01% | 2676 |
|
|
2019
Q4 | $8.05M | Buy |
240,395
+83,979
| +54% | +$2.35M | ﹤0.01% | 2155 |
|
|
2019
Q3 | $3.27M | Buy |
156,416
+101,491
| +185% | +$2.07M | ﹤0.01% | 2910 |
|
|
2019
Q2 | $1.14M | Sell |
54,925
-10,414
| -16% | -$214K | ﹤0.01% | 3773 |
|
|
2019
Q1 | $1.46M | Sell |
65,339
-9,864
| -13% | -$232K | ﹤0.01% | 3595 |
|
|
2018
Q4 | $1.8M | Buy |
75,203
+13,523
| +22% | +$350K | ﹤0.01% | 3359 |
|
|
2018
Q3 | $1.68M | Sell |
61,680
-765
| -1% | -$21.6K | ﹤0.01% | 3548 |
|
|
2018
Q2 | $1.68M | Sell |
62,445
-5,509
| -8% | -$169K | ﹤0.01% | 3594 |
|
|
2018
Q1 | $2.16M | Buy |
67,954
+4,796
| +8% | +$169K | ﹤0.01% | 3317 |
|
|
2017
Q4 | $2.39M | Buy |
63,158
+1,892
| +3% | +$61K | ﹤0.01% | 3228 |
|
|
2017
Q3 | $1.52M | Buy |
61,266
+2,025
| +3% | +$43.7K | ﹤0.01% | 3528 |
|
|
2017
Q2 | $1.22M | Sell |
59,241
-999
| -2% | -$19.1K | ﹤0.01% | 3587 |
|
|
2017
Q1 | $1.31M | Sell |
60,240
-3,448
| -5% | -$70.7K | ﹤0.01% | 3542 |
|
|
2016
Q4 | $1.3M | Buy |
63,688
+8,755
| +16% | +$179K | ﹤0.01% | 3499 |
|
|
2016
Q3 | $824K | Buy |
54,933
+3,454
| +7% | +$46.6K | ﹤0.01% | 3615 |
|
|
2016
Q2 | $558K | Sell |
51,479
-3,213
| -6% | -$43.7K | ﹤0.01% | 3849 |
|
|
2016
Q1 | $741K | Buy |
54,692
+47,985
| +715% | +$749K | ﹤0.01% | 3599 |
|
|
2015
Q4 | $124K | Buy |
6,707
+3,868
| +136% | +$71.6K | ﹤0.01% | 4762 |
|
|
2015
Q3 | $71K | Buy |
+2,839
| New | +$66.4K | ﹤0.01% | 5109 |
|
Wells Fargo's AIMT Position: Q4 2020 in Review
Wells Fargo sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 23,021 shares — an estimated $794K sold.
Wells Fargo first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $8.05M in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Wells Fargo reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Wells Fargo sold 23,021 Aimmune Therapeutics shares in Q4 2020, an estimated $794K.
- Wells Fargo first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
- Wells Fargo's Aimmune Therapeutics position peaked at $8.05M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Wells Fargo's 13F filing for Q4 2020, filed 9 Feb 2021.